LAUSR

e12508Background: Eribuline mesylate, is widely prescribed for MBC pts alone or in combination with Capecitabine in patients pretreated with at least 1-2 lines of chemotherapy, including anthracyclines and taxanes (A&T). Elderly Patients (EP) develop rapid and sometimes fatal toxicity during treatments due to pharmacokinetic features of these drugs.A combination schedule (E+C) to evaluate its suitability for VEW with MBC patients ,was used in this study. Methods: Treatment plan: E 0.96 mg/sqm IV on d1 every 21d - C 900 mg/sqm bid d1-14 every 28d (Dose-adjustement if necessary was according to Kintzel-Dorr’s formula for elderly), schedule administration continued until progression or intolerable toxicity. Eligibility criteria: histologically confirmed diagnosis of BC, 1 or more measurable lesion,(bone or visceral ) not brain mts, age > 75 years, failure of previous treatment with A or T , Comprehensive Geriatric Assessment evaluation (CGA) permissive for chemotherapy, adequate renal (CCl evaluation), bone ...